An assay that measured Ab-mediated inhibition of the ACE2/RBD (Wu-01 strain) interaction [21], yielded very similar results, detecting blockade in all controls, but in only 30% (28/95) of CLL patients (p < 0.001; S2–S4 Tables). This evidence concerns the gene ACE2 and B-cell chronic lymphocytic leukemia.